Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Item

http://www.wikidata.org/entity/Q38636154

Q38636154

about

PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas MicroRNAs in diffuse large B-cell lymphoma.Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma.Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score? Reply to Adams and Kwee.Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores.

P2860

Q26752284-719F6315-88D0-4CB5-821C-8B72FB7E8308 Q36524472-08F711A9-7F8B-4EEF-817E-A30694CF98F2 Q40373396-5C3554AD-75F3-45DC-B602-398A0C9F983A Q45530965-80BA0149-596F-413F-8B8F-F4FF31E458D3 Q48837806-0464D292-6BB8-48FE-A9AB-3DF9952FB78B Q48838255-6F56D1BE-021C-4B4D-AB12-F919110405EE Q53211003-610D6845-E7D3-459D-97BB-01D75ABFFB41

P2860

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

Item

http://www.wikidata.org/entity/Q38636154

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Delineating outcomes of patien ...... ; a population-based analysis.

@en

type

Item

label

Delineating outcomes of patien ...... ; a population-based analysis.

@en

prefLabel

Delineating outcomes of patien ...... ; a population-based analysis.

@en

P1476

Delineating outcomes of patien ...... ; a population-based analysis.

@en

P2093

Andrew K McMillan

http://www.w3.org/2001/XMLSchema#string

Andrew P Haynes

http://www.w3.org/2001/XMLSchema#string

Eleanor James

http://www.w3.org/2001/XMLSchema#string

Eric Bessell

http://www.w3.org/2001/XMLSchema#string

Faith Richardson

http://www.w3.org/2001/XMLSchema#string

Rakesh Ganatra

http://www.w3.org/2001/XMLSchema#string

Simon Hughes

http://www.w3.org/2001/XMLSchema#string

Vishakha Sovani

http://www.w3.org/2001/XMLSchema#string

P2860

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Positron-emission tomography and assessment of cancer therapy.

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

P304

246-254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13831

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

172

http://www.w3.org/2001/XMLSchema#string

P50

Mark Bishton

Christopher P Fox

P577

2015-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26577576

http://www.w3.org/2001/XMLSchema#string

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

about

P2860

P2860

Delineating outcomes of patients with diffuse large b cell lymphoma using the national comprehensive cancer network-international prognostic index and positron emission tomography-defined remission status; a population-based analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698